immune-checkpoint-inhibitors

Documents about immune-checkpoint-inhibitors

• Pharmacokinetic Study of Therapeutic Plasma Exchange#904769ClinicalTrials.gov
• The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis#4635Europe PMC
• Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors#1032986ClinicalTrials.gov
• Machine learning for Improving Risk Stratification of Hepatocellular Carcinoma (HCC) Patients Treated with Immune Checkpoint Inhibitors (ICIs)#13290DataCite
• Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors#322420HAL (France)
• Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.#343815ClinicalTrials.gov
• irAE Prediction of Anti-PD-1/L1 in Lung Cancer#346927ClinicalTrials.gov
• Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges.#418350NCBI PubMed Central
• Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy#253510Europe PMC
• Ursodeoxycholic Acid Alone Is Effective and Safe to Treat Cholestatic Checkpoint Inhibitor‐Induced Liver Injury#280347HAL (France)
• Patients with Cancer and Immune Checkpoint Inhibitor-Induced Rheumatic irAEs Treated by DMARDs: The RHUMICI Single-Centre Retrospective Cohort#922929HAL (France)
• Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer#274674IRIS
• Feasibility and Expansion Trial of Transcutaneous Vagus Nerve Stimulation (tVNS) for Immune-Related Fatigue in Patients Receiving Immune Checkpoint Inhibitors#180389ClinicalTrials.gov
• Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitors <i>via</i> regulation of the tumor microenvironment and gut microbiota#243827Europe PMC
• Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review#6851OpenAlex
• Myokine-mediated mechanisms of immune checkpoint inhibitors-associated colorectal injury and repair in rectal cancer.#636341NCBI PubMed Central
• Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors#883751ClinicalTrials.gov
• Supplementary file 1_Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.docx#1038752Figshare
• Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival#268889IRIS
• Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma#4567Europe PMC
• Exploration of the Predictive Marker and Establishment of Predictive Models of Checkpoint Inhibitor Pneumonitis#839611ClinicalTrials.gov
• TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC#868195ClinicalTrials.gov
• Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma#249609ClinicalTrials.gov
• Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors#804531ClinicalTrials.gov
• Non-tuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review#988065IRIS
• Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer#897228ClinicalTrials.gov
• Mortality and Cancer Response in Patients with Immune Check Point Inhibitor Associated Uveitis#922293Figshare
• Highly activated CD4+ T regulatory cells associated with non- responders to immune-checkpoint inhibitors in metastatic melanoma#123343Europe PMC
• A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability#326109HAL (France)
• Observational Cohort Study of Chronic Viral Infection in the Central Nervous System#813886ClinicalTrials.gov
• Microbiome Immunotherapy Toxicity and Response Evaluation#843036ClinicalTrials.gov
• The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma#268874IRIS
• Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors#474874ClinicalTrials.gov
• Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS.#199204NCBI PubMed Central
• Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer#373585ClinicalTrials.gov
• The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy#426763ClinicalTrials.gov
• Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.#437127NCBI PubMed Central
• Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr#628522ClinicalTrials.gov
• Global research trends in fecal microbiota transplantation combined with immune checkpoint inhibitors for cancer immunotherapy: a bibliometric analysis.#685707NCBI PubMed Central
• cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors#834443ClinicalTrials.gov
• Ago2 loss restores sensitivity to immune checkpoint inhibitors in immunorefractory lung cancer#923048HAL (France)
• Associations between spatial distribution of immune cell subsets and clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors: results from the PUMA challenge#414799Europe PMC
• Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma#864397ClinicalTrials.gov
• Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study#979049ClinicalTrials.gov
• Highly activated CD4+ T regulatory cells associated with non- responders to immune-checkpoint inhibitors in metastatic melanoma#130420Unpaywall
• Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors#326130HAL (France)
• Defining the Role of the Skin Microbiome in Immune-related Adverse Events#802183ClinicalTrials.gov
• Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer#898078ClinicalTrials.gov
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma#914260ClinicalTrials.gov
• Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real‐world study#239056HAL (France)